SGI-1776

DRUG2 trials

Sponsors

Astex Pharmaceuticals, Inc.

Conditions

Non-Hodgkins LymphomaProstate CancerRelapsed/Refractory Leukemias

Phase 1

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

TerminatedNCT00848601

Astex Pharmaceuticals, Inc.Non-Hodgkins Lymphoma, Prostate Cancer

Start: 2009-02-28End: 2010-10-31Updated: 2024-08-02

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

WithdrawnNCT01239108

Astex Pharmaceuticals, Inc.Relapsed/Refractory Leukemias

Start: 2010-10-31End: 2012-04-30Updated: 2024-08-02